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ABSTRACT 
 
 
SYNTHESIS OF TIME-RESOLVED FLUORESCENCE PROBES FOR THE FUTURE DETECTION 
AND IMPROVED STUDY OF CANCER 
Alyssa M. Frediani, M.S. 
Western Carolina University, October 2019   
Director: Dr. Brian Dinkelmeyer 
 
The goal of this project is to develop a diagnostic tool for detecting melanoma cells.  The design entails 
using a polyethylene glycol (PEG) linker to attach a luminescent lanthanide complex to a peptide (MSH-
4) that specifically targets G-protein coupling receptors on melanocytes.  Lanthanide chelate labels, such 
as europium thenoyltrifluoroacetone (Eu(TTA)3), have great potential as imaging and detection agents 
since their luminescent properties allow them to be visualized with high efficiency over the fluorescence 
of a biological background. The synthesis of each component; linker, ligand, complex and peptide was 
attempted.  The MSH-4 protein was successfully synthesized on a Rink-amide resin using an FMOC 
protection/deprotecting as evidenced by positive ninhydrin tests after each coupled amino acid.  The 
phenanthroline amine ligand was successfully synthesized as well as its europium complex made.  The 
quantum yield for the Eu(TTA)3-5-amine-1,10-phenanthroline complex was measured and was 
determined to be sufficient for our purposes.  However, difficulties arose in attaching the PEG linker to 
the phenanthroline amine ligand.  The amine functional group was too poor of a nucleophile to react with 
an O-tosylated PEG linker.  This unforeseen challenge necessitated a change in the synthetic strategy.  
The idea came to add a functional group with a better leaving group. This led to using bromo acetic 
anhydride to convert the amine to a bromo acetamide. The reaction to couple this anhydride to the 
phenanthroline amine ligand was deemed successful by using proton and carbon NMR.  The quantum 
yield of the new acetamide-phenanthroline ligand had reduced quantum yield as compared to the 
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originally proposed ligand. This was investigated and concluded that the weaker electron-donating ability 
of the amide in this compound that is correlated to the carbonyl, negatively impacted the fluorescence of 
the europium complex.  Future work will investigate coupling the monosubstituted PEG linker with the 
ligand by nucleophilic substitution of the bromine.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3 
 
CHAPTER 1: INTRODUCTION 
1.1 Background 
Melanoma cancer rates have seen an overall increase over the past 20 years; however, melanoma cancer 
has the one of the lowest mortality rates amongst all forms of cancer, being only 1.5%. For the year of 
2019, it is projected that 99,000 new cases of melanoma will affect the Unite States population. With that 
projection, 13,000 cases will assume to be fatal. 1 Melanoma cancer can mutate anywhere on the body 
that there are melanocytes. This includes skin, eyes, and even fingernails.  Melanoma tumors can appear 
as moles, abrasions, or sores on the external organs of the body.  If untreated, melanoma tumors will grow 
large enough to penetrate beneath the dermis, approximately 1mm into the skin, and to the blood vessels 
at which point it is called metastatic melanoma.2 Metastatic melanoma releases cells into the body that 
can spread into lymph nodes and various organs causing the start and spread of more fatal cancer cells 
throughout the person affected.  If caught early, melanoma, or suspected lesions, can be removed  by 
minor surgical procedures for biopsy.3 Early detection is critical in lowering the fatality rate for patients  
with melanoma cancers.  A common method of biopsy is to observe the cells under a fluorescent 
microscope to further inspect abnormalities microscopically. In this technique, the sample is first stained 
with a fluorescent dye.  This detection of diseased cells can be difficult because current dyes and 
biological cell samples, both fluoresce at short wavelengths making it difficult to differentiate between 
abnormal and normal cells.  An improved detection method would use a dye that fluoresces at a vastly 
different wavelength from the cell background and would specifically bind to melanoma cells.  
The most commonly targeted signaling pathway in eukaryotic cells involves G protein coupled 
receptors (Figure 1). In fast growing melanocytes, MSH-G protein coupled receptors (GPCR) are 
overexpressed on their cell surfaces.  A high concentration of GPCR can be linked to the rapid expansion 
of tumor growth.4  Easy detection of these protein coupled receptors would improve the chances for early 
detection of melanoma cancer.   This receptor acts as the inbox to the cell allowing it to translate and send 
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messages. The GPCR can be stimulated by the introduction of an agonist which can be in the form of 
light, proteins, sugars, lipids and peptides.   
 
Figure 1: G-protein coupling receptor stimulated by a signaling molecule (agonist). 
The prospective probe includes linking a GPCR targeting peptide, melanocyte stimulating 
hormone (MSH-4), to a chelated lanthanide ligand. This is expected to enhance the fluorescence of 
melanocytes against normal biological sample background fluorescence by fluorescing at much longer 
wavelengths while absorbing at shorter wavelengths. The attachment of the highly luminescent lanthanide 
to MSH-4 will produce a fluorescent dye with high specificity for melanoma cancer cells.  
1.2 Project Goal 
The overall goal of this project is to develop a diagnostic tool for detecting melanoma cells.  The design 
from left to right, displayed in Figure 2, entails attaching a luminescent lanthanide chelate to a 
polyethylene glycol (PEG) linker attached to a peptide, MSH-4, that targets and binds to a G-protein 
coupling receptor found on the surface of and excreted by melanoma cancer cells. The success of this 
proposed structure relies heavily on making sure the chelated lanthanide ligand does not interfere with the 
MSH-4 peptide. The interference could hinder the probe’s ability to attach properly to the GPCR. This 
would then interfere with the lanthanides ability to fluoresce properly. Since the peptide is specifically 
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designed for the GPCR of melanocytes, the probe will not be able to attach to any other GPCRs in any 
residual biological cells.  
 
Figure 2: Design of Fluorescent Melanoma Probe 
The design of this compound is related to a series of techniques called bioconjugation. 
Bioconjugation allows bonds between a biological molecule and a synthesized molecule to form.6 
Considering that the molecule being proposed needs an amalgamation of synthetic and biologic 
properties, this will make it a more useful and successful system for site specified conjugation. The 
method for bioconjugation of the desired compound includes MSH-4 that is conjugated to a lanthanide 
chelated ligand, by separation of a PEG linker.   
PEGylation has been making large advancements in the field of anti-cancer therapy.7 The PEG 
units are used to separate bioactive sites from a cell targeting drug, or in relation to this project design, a 
luminescent lanthanide chelate label that would be used for imaging. Polyethylene glycol has some of the 
most desired properties for pharmaceuticals. These properties include being nontoxic, non-immunogenic, 
and hydroscopic.7 These properties associated with PEGylation allow for biopharmaceuticals to change 
their physical and chemical properties. This aids in cell interpretation of the molecule, so that the PEG 
linker can enhance the retention time that the drug remains in the targeted cell as well as protects them 
from rapid degradation.8 The PEG linker also acts as a separation unit between the MSH-4 peptide and 
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the lanthanide chelated ligand to prevent steric hinderance. For this project a monosubstituted benzyl-
PEG will be used for the bioconjugation of the proposed molecule. 
Lanthanide complexes are used in a wide array of bioimaging applications. These complexes have 
desirable properties that aid in their success and reliance. The properties include narrow emission bands 
and long luminescence lifetimes9.  The lanthanide being used for this project is Eu3+. The narrow emission 
bands stem from the 4f orbitals of the lanthanide (III) ions being shielded by the full 5s and 5p sub-shells. 
The 4f-4f electronic transitions of the europium ions are forbidden by the electric dipole selection rules.9 
These rules state that the transition is forbidden because the initial and final state of the orbital 
symmetries are the same. These forbidden transitions of direct excitation of f-f electrons are an inefficient 
luminescent characteristic of europium ions.9 Because of this difficulty of direct excitation of the 
lanthanide (III) ion and performing an f-f transition is rare, an organic chromophore can be utilized to aid 
in the transfer of energy to the lanthanide (III) ion, Figure 4. To enable the transfer of energy, light energy 
is passed onto lanthanide (III) ion from the organic ligand. The ligands are able to absorb light and 
transfer the energy from the light to the lanthanide. This is known as the antenna effect shown in Figure 3.    
 
Figure 3: Illustration of the antenna effect of an organic ligand chelated to a lanthanide (III) ion. 
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Figure 4: Jablonski diagram showing the energy transfer from the excited state of the ligand to the 
excited state of the europium ion and to the ground state via luminescence.
 
Europium (III) complexes that are paired with beneficial organic ligands have several advantages over 
other lanthanide (III) complexes as bio-imaging agents. One of the advantageous characteristics of Eu3+ 
complexes is that they are sensitive to longer wavelengths of light (visible range) which has fewer 
negative effects on biological analytes such as cells and tissues, than UV light excitation.  Also, Eu3+ 
complexes have narrow emission bands that emit reddish orange light which has minimal interference 
with the luminescence emission of biological samples.10 In addition, Eu3+complexes have large Stokes 
shifts, long luminescent lifetimes, and high luminescence quantum yields.9  These characteristics make 
Eu3+ complexes extremely useful agents to utilize organic chromophores for biomedical imaging 
applications.  
The MSH-4 peptide is a specially designed chain of amino acids to target the GPCR of melanocytes. 
Therapeutic peptides have made several advancements in cancer detection and treatment. The advantages 
of using therapeutic peptides include low toxicity, higher target specificity and selectivity, and they are 
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easy to synthesize12. For the synthesis of the MSH-4 peptide, solid phase peptide synthesis will be 
utilized. 
Solid phase peptide synthesis is a highly successful technique which is used for large biomolecules 
that include peptides and proteins. Some of the advantages to this technique include, higher yields, faster 
and more efficient reactions, and minimal purification12. The higher yields are common because the 
amino acids and coupling reagents can be used in extreme excess. Excess and unreacted reagents are 
easily removed by filtration, allowing for purification of the peptide to be easy and efficient. The overall 
process of solid phase peptide synthesis comprises a step by step construction of amino acids on an 
insoluble polymer support resin. This is done by coupling the amine group of one amino acid to the 
carboxylic acid functional group of the next amino acid to form an amid bond. 
1.3 Synthetic plan 
The project requires synthesizing a PEGylated-ligand that can be easily coupled to an MSH-4 peptide.  
The MSH-4 peptide will be synthesized using microwave assisted solid-state peptide synthesis.   1,10-
phenthroline ligand was selected since it is known to make stable highly fluorescent complexes with 
europium (III) thenoyltrifluoroacetone.  The synthetic strategy is shown in Scheme 1.  Attaching the 
ethylene glycol to the ligand will require adding an amine group by first nitration of phenanthroline 
followed by reduction to an amine.  This resulting 5-amino-1,10-phenthroline 2 can then be converted to a 
Bromo acetamide derivative 3 which can then be reacted with a benzyl protected tetra ethylene glycol 9 to 
produce compound 10.  Deprotection and oxidation of 10 will produce a PEGylated-ligand that can be 
attached directly to the MSH-4 peptide while it is still attached to the resin.   
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Scheme 1: Synthetic plan of overall project 
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CHAPTER 2: EXPERIMENTALS 
All starting materials were purchased by Western Carolina University Department of Chemistry and 
Physics from Fisher Scientific, Acros Organics, and Alfa Aesar and used without further purification.  
Chloroform and dichloromethane were dried before use by sitting for at least 48 hours over 3Å sieves. 
Spectral Data were collected by means of nuclear magnetic resonance (NMR), fourier-transform infrared 
spectroscopy (FT-IR), UV-Vis, and fluorescence. All instruments used to obtain data were located at 
Western Carolina University.  
2.1 Instrumentation 
2.1.1 Nuclear Magnetic Resonance Instrumentation  
The instrument used for NMR spectroscopy is a JEOL 300 MHz Eclipse NMR. This instrument utilizes a 
5mm tunable probe to detect 1H, 13C, 19F, and 31P. For the premise of this project, only 1H and 13C were 
measured using this instrument. The measured samples for 1H NMR were prepared by dissolving 
approximately 10-20 mg of analyte in deuterated chloroform or deuterated dimethyl sulfoxide and set for 
a minimum of 8 scans to a maximum of 24 scans to gain more precise measurements. For 13C NMR the 
samples were dissolved in deuterated solvents until a readable saturation level was achieved and set for a 
maximum of 2400 scans.  
2.1.2 Fourier-Transform Infrared Instrumentation 
The instrument used for FT-IR spectroscopy is a Perkin-Elmer Spectrum One. This instrument analyzes 
materials using single bounce attenuated total reflectance (ATR) infrared technology, with measurements 
collected in the range of 4000 cm-1 to 600 cm-1. All analytes were measured at room temperature with a 
background measurement collected before each measurement.  
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2.1.3 Ultraviolet-Visible Instrumentation 
The instrument used for UV-Vis spectroscopy is an Agilent 8453 Diode Array Spectrometer. This 
instrument utilized both tungsten and deuterium lamps to be able to take measurements from 190 nm to 
1100 nm. This spectrometer has a slit width of 1 nm to ensure that a 1nm gradient of light is shown at the 
sample for each measurement. The samples were prepared by dissolving the sample in dichloromethane 
or methanol and transferred to a quartz cuvette with a 1.0 cm path length.  The samples were diluted 
accordingly until the desired absorption level was achieved. The measurements were made at room 
temperature with a blank cuvette filled with the respective solvent measured first to subtract background 
noise from the spectra.  
2.1.4 Fluorescence Instrumentation  
The instrument used for fluorescence spectroscopy was a Perkin-Elmer LS-55 Fluorometer. This 
instrument uses a xenon pulse lamp and highly sensitive, holographic gratings to ensure the spectra 
gathered is accurate and reproducible. This spectrometer has a slit width of 0.1 nm to keep stray light 
interference as minimal as possible. The sample is prepared in a quartz cuvette with a 1.0 cm path length 
using the same sample preparation in section 2.1.3. The previously measured UV-Vis absorption 
wavelength of each sample was used to excite the sample to achieve its fluorescence emission. All 
measurements were made at room temperature. 
2.1.5 Quantum Yield Measurements 
The UV-Vis and fluorescent measurements were used to calculate the luminescent quantum yield 
according to equation 1. The quantum yield is used to measure the fluorescence efficiency of the 
europium complexes synthesized in this study.  Quantum yield is simply the ratio of the number photons 
emitted to the number of photons absorbed.     
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 Equation 1     
𝜙𝑆 = 𝜙𝑅
𝐴𝑏𝑠𝑅
𝐴𝑏𝑠𝑆
𝐴𝑆
𝐴𝑅
𝑛𝑆
2
𝑛𝑅
2  
 
Where Abs is the absorbance, A is the area under the luminescence curve, and n is the refractive index of 
the solvent. The subscripts R and S are representative of reference sample and sample respectively. Phi 
(φ) is representative of quantum yield itself. The reference sample that was used was Cresyl violet, with a 
known quantum yield of 0.54, or 54% using methanol as the solvent.  
2.2 Synthetic procedures 
2.2.1 Europium thenoyltrifluoroacetone water complex, (Eu(TTA)3(H2O)2)  [4].17   
NaOH pellets (3.36 mmol, 0.1467 g, 3 eq) was dissolved in 20 mL of water and a magnetic stir bar was 
added.  Thenoyltrifluoroacetone (tta) (3.41 mmol, 0.7622 g, 3 eq) was added to the NaOH solution and 
allowed to stir at room temperature for 10 minutes.  A second solution consisting of EuCl3·6H2O (1.13, 
0.4193 g, 1 eq) dissolved in 12 mL of water and allowed to a stir at room temperature. The NaOH/tta 
solution was then added dropwise to the europium solution. A white/yellow precipitate immediately 
formed. Once all of the solution had been added, a septum was placed on the round bottom flask and the 
solution stirred under argon for 3 hours at 60˚C. The cream-colored Eu(TTA)3(H2O)2 precipitate was 
isolated by vacuum filtration and with rinsed with 100 mL of water twice and with 3 mL of hexanes once. 
The complex as characterized using UV-Vis and Fluorescence spectroscopy in methylene chloride and 
was used without further purification. Yield: 0.7846 g (83%) UV (CH2Cl2) λmax, 340 nm.  Fluorescence 
(CH2Cl2) λexcitation, 340 nm, λemission, 615 nm 
2.2.2 5-nitro-1,10-phenanthroline ligand, (nitro-phenanthroline) [1].14  
1,10-phenanthroline (5.65 mmol, 1.0185 g, 1 eq) was added to a 25 mL round bottom flask with a 
magnetic stir bar. Concentrated sulfuric acid (126.03 mmol, 6.0 mL, 3 eq) was added slowly to the round 
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bottom flask.  The reaction vessel was fitted with a reflux condenser and fuming nitric acid (112.56 
mmol, 3.0 mL, 6 eq) was carefully added dropwise into the round bottom flask. A reddish-brown gas was 
produced while the nitric acid was being added.  The solution stirred at room temperature for 15 minutes. 
The round bottom flask was then placed into a paraffin oil bath and refluxed at 160˚C for 3 hours.  The 
reaction mixture was allowed to cool to room temperature and poured over ice in a 150 mL Erlenmeyer 
flask.  Once the ice had melted, the pH of the solution was carefully adjusted to a pH of 3 to induce 
precipitation using saturated NaOH solution.  Product yield was negatively affected if the pH was 
adjusted higher than 3.  The yellow solid was collected by vacuum filtration and was washed with water 
and allowed to air dry overnight. Yield= 0.9670 g (76%).  1H-NMR 300MHz (CDCl3): δ 9.3 (2H mult.), δ 
8.99 (1H, dd), δ 8.64 (1H, s), δ 8.41 (1H, dd), δ 7.79 (2H, mult.).  C13 NMR(CDCl3): 156.432, 153.655, 
151.563, 147.654, 146.207, 144.270, 137.994, 132.558, 125.634, 124.521, 121.049 ppm.   IR (ATR): 
3023, 1505, 1349, 1144, 805, 731 cm-1.  
2.2.3 5-amine-1,10-phenanthroline ligand, (amine-phenanthroline) [2].15   
Previously synthesized nitro-phenanthroline (1.107 mmol, 0.2573 g, 1 eq) was dissolved in 20 mL of 
absolute ethanol in a 50 mL round bottom flask.  Dissolution of the nitro-phenanthroline required 
sonication for 5-60 minutes.  Once dissolved, argon was bubbled through the solution to displace any 
dissolved oxygen and then 5% palladium on carbon (25.0mg) was added.  A stir bar and a rubber septum 
were added and the reaction vessel was purged with argon gas.  Hydrazine (19.375 mmol, 0.7 mL, 19 eq) 
was added dropwise via syringe over a period of 15 minutes. The round bottom flask was placed in an oil 
bath and heated to 70˚C. The solution was allowed to stir at 70˚C overnight.  The Pd/C catalyst was 
removed by vacuum filtering the solution through a celite plug. The filtrate was diluted with chloroform 
and washed 3 times with water. The solvent was removed under reduced pressure using a rotary 
evaporator to produce a brick red solid. Yield: 0.1376 g (63%). H1 NMR (CDCl3):   9.208  (1H, dd),  
8.95 (1H, dd),  8.29 (1H, dd),  8.00  (1H, dd),  7.67 (1H, qt),  7.51 (1H, qt),  6.96  (1H, s), C13 
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NMR(CDCl3 ) 149.935, 146.899, 146.599, 142.180, 139.858, 133.434, 129.782, 129.411, 123.224, 
122.194, 122.088, 105.486 ppm.   IR (ATR): 3338, 3220, 1609, 1491, 1408, 862, 738, 628 cm-1.  
2.2.4 2-bromo-N-(1,10-phenanthroline-5-yl) acetamide hydrobromide (BPAH) [3].16 
  5-amine-1,10-phenanthroline was dried before use by dissolving it in toluene followed by rotary 
evaporation.  The dried 5-amine-1,10-phenanthroline (0.4018 g, 2.06 mmol, 1 eqv) was added to an oven 
dried 100ml round bottom flask and dissolved in 40 mL of anhydrous chloroform.  The round bottom 
flask was fitted with a reflux condenser and a septum and purged with argon. A solution consisting of 
Bromo acetyl bromide (0.31 mL,4.18 mmol, 1.2 eqv) in 40 mL of dry chloroform was added slowly to the 
100 mL round bottom flask over 3 to 5 minutes. The reaction mixture was refluxed overnight. The 
resulting solid was isolated by vacuum filtration and recrystallized by hot filtration form methanol. Yield: 
0.4078 g (63%) Characterized by carbon and proton NMR and IR. 1H-NMR 300MHz (DMSO-D6): δ 
10.92 (1H, s), δ 9.35 (1H, dd), δ 9.23 (1H, dd), δ 9.06 (1H, dd), δ 8.59 (1H, s)   C13-NMR 300MHz 
(DMSO-D6): δ 172.387, 166489, 149.191, 145.311, 143.347, 143.042, 136.199, 135.625, 134.957, 
133.067, 129.452, 125.705, 125.213, 118.668, 61.962, 30.042 cm-1. IR (ATR): 3028, 2909, 1711, 1540, 
1496, 1413, 1202, 878, 799, 724 cm-1.  
2.2.5 Eu(tta)3(1,10-phenanthroline) [5]18 
Eu(tta)3(H2O)2 (0.1195 mmol, 0.1097 g, 1 eq) was added it to a 100 mL round bottom flask with 30 mL of 
methylene chloride and a magnetic stir bar. In a 50 mL Erlenmeyer 1,10-phenanthroline (0.1195 mmol, 
0.0274g, 1 eq) and 30 mL of methylene chloride were added and dissolved with a magnetic stir bar. The 
phenanthroline solution was then added the europium solution dropwise. The round bottom flask was then 
added to an oil bath to 60˚C and allowed to stir overnight. The solution was gravity filtered into a 100 mL 
Erlenmeyer flask and then allowed the solvent to evaporate by air. Characterized by UV-Vis and 
Fluorometer using methylene chloride as the solvent. UV (CH2Cl2) λmax, 344 nm.  Fluorescence (CH2Cl2) 
λexcitation, 340 nm, λemission, 615 nm. QY: 4.83 ± 0.815% 
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2.2.6 Synthesis of Eu(tta)3(5-nitro-1,10-phenanthroline) [6] 
This synthesis was preformed using identical synthetic procedures as section 2.2.5; although 5-nitro-1,10-
phenanthroline (0.1195 mmol, 0.0273 g, 1 eq) was used. Characterized by UV-Vis and Fluorometer using 
methylene chloride as the solvent. UV (CH2Cl2) λmax, 344 nm.  Fluorescence (CH2Cl2) λexcitation, 340 nm, 
λemission, 615 nm. QY: 2.78 ± 0.523% 
2.2.7 Synthesis of Eu(tta)3(5-amine-1,10-phenanthroline) [7] 
This synthesis was preformed using identical synthetic procedures as section 2.2.5; although 5-amine-
1,10-phenanthroline (0.1195 mmol, 0.0243 g, 1 eq) was used. Characterized by UV-Vis and Fluorometer 
using methylene chloride as the solvent. UV (CH2Cl2) λmax, 342 nm.  Fluorescence (CH2Cl2) λemission, 
615 nm. QY: 5.02 ± 1.14% 
2.2.8 Synthesis of Eu(tta)3(BPAH) [8] 
This synthesis was preformed using identical synthetic procedures as section 2.2.5; although BPAH 
(0.1195 mmol, 0.0438 g, 1 eq) was used. Characterized by UV-Vis and Fluorometer using methylene 
chloride as the solvent. UV (CH2Cl2) λmax, 346 nm.  Fluorescence (CH2Cl2) λemission, 615 nm. QY: 0.417 
± 0.107% 
2.2.9 Synthesis of monobenzyl protected polyethylene glycol linker (Bz-4EG) [9]19 
Tetra-ethylene glycol (60.0 mL, 60.54 g, 0.312 mol, 3.95eqv.) was added to 165 mL of 50% v/v NaOH 
aqueous solution and stirred at room temperature for 20 min.  Benzyl bromide (10.8 mL, 15.552 g, 0.091 
mol, 1.0 eqv.) was then added to the solution. The solution refluxed and stirred for 24 hours and cooled at 
room temperature. The mixture formed two layers; the top a dark, syrup layer and the bottom a 
transparent orange layer. The top layer was removed and diluted with water (50 mL). The pH was 
adjusted to 4 using 2.0 M HCl. The solution was then extracted with diethyl ether (50 mL) three times, 
washed with a brine solution, and then dried over magnesium sulfate. The solvent was removed by rotary 
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evaporation. The product was a mixture containing both mono and di benzyl substituted PEG. The 
separation of this mixture was done by using column chromatography in a 1:1 ethyl acetate/hexane 
solution, while the solution increased in concentration of ethyl acetate. The product was characterized 
using carbon and proton NMR and FT-IR. Yield: 6.66 g (74%) H1 NMR 300MHz, (CDCl3) : δ 3.66(16H, 
m), δ 4.56(2H, s), δ 7.33 (5H, d).   C13 NMR 300MHz, (CDCl3): 61.72, 69.39, 70.31, 70.58, 70.60, 72.90, 
73.23, 127.59, 127.76, 128.34, 138.16 ppm.  IR(ATR): 3443, 2866, 1719, 1453, 1350, 1093, 939, 885, 
738, 698 cm-1. 
2.2.10 Synthesis of MSH-4 peptide [10]20-21 
The peptide was synthesized using traditional microwave assisted FMOC procedures and solid phase 
peptide synthesis. The microwave used was a Discover SP-X microwave synthesizer equipped with a 
fiber optic temperature probe manufactured by CEM Corporation. A low loading (0.10-0.30 mmol/g) rink 
amide resin was the solid support for binding.  500 mg of resin was weighed and swelled for 40 minutes 
at room temperature in a 50:50 (by volume) mixture of DMF and DCM.  After swelling was complete the 
solvent was filtered from the resin.  The beginning FMOC protecting group was removed by adding 3 mL 
piperidine to the fritted microwave vessel. To ensure that the microwave temperature was consistent, a 
fiber optic temperature probe was inserted into the reaction vessel to direct the microwave to stop once 
the preferred temperature was reached.  The microwave settings for the deprotection method adjusted the 
power to 50 W and heated the reaction to a maximum of 70˚ C for 30 seconds.  Following deprotection, 
the resin beads were washed and filtered three times with 2 mL of DMF to elute excess reagents.  A 
Kaiser test was performed to indicate a free amine group. This was done by removing a few resin beads 
which were added to a test tube with the Kaiser reagent and heated in the microwave at 120˚ C for 30 
seconds.  A positive Kaiser test exuded a blue color for successful deprotection. Next, the first amino acid 
was coupled to the resin. For this, DIC and ethyl (hydroxyamino)cyanoacetate were used in a 5x molar 
excess as coupling reagents. The reagents were combined with a 5x excess of the amino acid and 
dissolved in DMF. This solution was added to the reaction vessel with the unprotected resin. The reaction 
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conditions included a maximum temperature of 75˚ C for 7 minutes. The resin was then washed and 
filtered three times with 3 mL of DMF. A positive Kaiser test was needed between each coupling to move 
to the next step. This process was repeated for each amino acid in the order of tryptophan, arginine, 
phenylalanine and histidine. The peptide was cleaved from the resin at room temperature using a rocker. 
The cleavage solution included 82.5% TFA, 5% thioanisole, 5% water, 5% phenol, and 2.5% 1, 2-
ethanedithiol (percentages are v/v-based values).  The peptide was cleaved for a minimum of 3 to a 
maximum of 6 hours. The resulting solution included the peptide whilst the resin beads remained to be 
filtered. The peptide solution was allowed to evaporate at room temperature until the volume was reduced 
by half. The peptide was then precipitated from solution using cold diethyl ether and being placed in the 
freezer for a minimum of 1 hour and a maximum overnight. The peptide precipitate in solution was then 
centrifuged at 0 ˚C for 20 minutes. Diethyl ether remained as the supernatant and was decanted from the 
solid peptide at the bottom of the centrifuge tube. The peptide was sonicated into diethyl ether and 
centrifuged twice to purify. The remaining solid was dried overnight by air, dissolved in a 50:50 mixture 
of acetic acid and water and lyophilized for 8 hours. The sample was characterized and verified by Dr. 
Matthew Vergne of Lipscomb University in Nashville, TN using LC/MS.  
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CHAPTER 3: RESULTS AND DISCUSSION 
The ultimate goal of this project is to develop a diagnostic tool for detecting melanoma cells.  The design 
entails attaching a luminescent lanthanide chelate to a polyethylene glycol (PEG) linker attached to a 
melanocyte stimulating hormone (MSH-4) that targets and binds to a G-coupling protein receptor found 
on the surface of and excreted by melanoma cancer cells. The success of the synthesis of this proposed 
structure relies heavily on making sure the chelated lanthanide ligand does not interfere with the MSH-4 
peptide. The interference could hinder the probe’s ability to attach properly to the GPCR. This would then 
interfere with the lanthanides ability to fluoresce properly. Since the peptide is specifically designed for 
the GPCR of melanocytes, the probe will not be able to attach to any other GPCRs in any residual 
biological cells. 
3.1 Synthesis of the MSH-4 peptide 
The MSH-4 peptide was synthesized using a microwave assisted FMOC synthesis procedure. Each 
peptide was added in series following standard deprotection/protection synthesis. There were few 
difficulties when synthesizing the peptide. One being that the deprotection step was needed to be repeated 
to ensure that the vast majority of the amino acids were deprotected and available to have the next amino 
acid attach to the sequence. If this step wasn’t repeated and checked then that would have resulted in 
lower yield of complete and correct peptide sequences. To ensure proper assembly and reduce error, a 
checklist was created, see supplemental materials for compound 10. This allows for other members to 
follow proper FMOC protocol, as well as help troubleshoot common errors if necessary.   
 For the characterization methods of the MSH-4 peptide, Western Carolina University does not 
have a LC/MS, therefore the sample peptides that were created and purified in the lab, had to be shipped 
to and analyzed by Dr. Matthew Vergne of Lipscomb University in Nashville, TN. They were verified by 
Dr. Vergne to be the MSH-4 peptide that was being designed for this project. The spectra is referenced in 
supplemental materials for compound 10. 
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3.2 Synthesis of 1,10-N,N-phenanthroline ligands 
The synthesis of each phenanthroline ligand began by using commercially synthesized N,N-1,10-
phenanthroline and then nitrating it at the 5th carbon using concentrated sulfuric acid and then adding 
fuming nitric acid dropwise. This allows for control of the reaction and ensuring that the gas production is 
under control. The resulting reaction mixture was added to ice to allow for rapid cooling and preparation 
for pH adjustment. The pH was neutralized to a pH of 3 using NaOH. The importance of this step was to 
allow for any remaining acid to be protonated and dissolvable in water, whilst allowing the resulting 
product to precipitate from solution. The solid was washed with water and allowed to dry.  The 5-nitro 
1,10phenathroline (1) was sufficiently pure for use in the next reaction. 
 The reduction of the nitro group of 1 to an amine was done by adding an excess of hydrazine 
dropwise to a solution of 1 in absolute ethanol containing a catalytic amount of palladium on activated 
charcoal.  Argon was bubbled through ethanol/1 solution to remove any dissolved oxygen before the 
hydrazine was added.  The reaction was heated to 70o C and stirred overnight under an inert atmosphere 
overnight. This allows for the nitro group of 1 to be reduced to form 5-amino 1,10phenathroline (2).  
 
 
 
 
Figure 5. Synthetic scheme for nitration and reductive amination of 1,10-phenanthroline. 
The original project plan was to attach the peg linker to the phenanthroline linker by performing a 
SN2 reaction between aminephenanthroline (2) with a mono-tosylated mono-benzylated tetra ethylene 
glycol (Fig 6). Previous attempts by another researcher were unsuccessful. Multiple attempts varying 
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solvent and base failed in producing the product.13 It was determined that the amino group attached to the 
aromatic ring was too poor of a nucleophile. Next, DCC peptide coupling methods were attempted using a 
ethylene glycol containing a carboxylic acid.  After several attempts using traditional peptide coupling 
methods the product could only be produced in low yields (Fig. 6).  One possible reason for failure may 
have been the difficulty in drying the starting materials.  Both phenanthroline and polyethylene glycol are 
difficult to keep dry and any excess water can react with DCC.  The synthetic plan was then rerouted to 
add another functional group to the phenanthroline that might be more practical (Fig 7). 
 
 
 
 
  
 
Figure 6.  Previous attempts to attach PEG to phenanthroline ligands.  a) Nucleophile attack of 
phenanthroline amine on a O-tosylated tetra ethylene glycol.  b)  peptide coupling methods were 
attempted to attach the PEG to the ligand.   
 
 
.  
 
Figure 7.  Adding a bromo acetamide group to the phenanthroline ligand may allow attaching PEG using 
an SN2 reaction where the PEG acts as the nucleophile.  
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Figure 8. Synthetic strategies to form the bromo acetamide attached to the amine. 
This led to trying to form a bromo acetic anhydride using bromo acetic acid and coupling it to the 
previously synthesized 2. This was attempted done using dry ethyl acetate and acetonitrile as solvents and 
dicyclohexylcarbodiimide as the coupling reagent. After several trials this reaction proved ineffective.  It 
was believed that the water associated with the phenanthroline amine 2 was interfering with the reaction.  
The next plan of action was to perform the same reaction, but separate it by first forming the anhydride in 
a separate reaction vessel.  The formation of the anhydride was confirmed by FTIR. The next step was to 
try react the anhydride with 2. This was done in dichloromethane and was deemed unsuccessful by H1 
NMR. It seems that the amine of 2 is too poor of a nucleophile to react with an anhydride.   The final 
attempt to attach a bromo acetyl group to 2 was by reacting the amine with bromo acetyl bromide. The 
acid bromide is a stronger is a stronger electrophile than an anhydride and should react even with a poor 
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nucleophile. This reaction was carried out using dry chloroform as the solvent and under inert 
atmosphere. The resulting precipitate was filtered and purified using hot recrystallization in methanol.  5-
N-bromoacetylphenathroline 3 was successfully synthesized as determined by H1 and C13 NMR as well as 
IR.  However, in the C NMR there is a peak of interest at 172 ppm. This peak correlates to a carbon that is 
part of a carboxylic acid functional group; therefore, more investigation needed to be done to eliminate 
whether or not there is a bromine on the targeted compound. This was done by preforming the flame test. 
The flame test can help determine whether or not a compound has a halogen within the system. A positive 
test for bromine would show a green flame when the compound is heated over a Bunsen burner. To carry-
out this test a copper wire was burnt over flame until an orange flame was at glow. Copper ions turn 
flame green, so this was done to eliminate the possibility of a false positive. The wire was then cooled and 
dipped into bromo acetyl bromide and then held over flame to verify that the color that should be 
displayed is green. Then wire was then held over flame until the flame turned orange, again to make sure 
that all excess would be burnt off to prevent false positive.  Compound 3 was then tested and showed a 
positive result for bromine in the sample. Therefore, the peak at 172 can be ruled as an impurity and that 
the synthesis deemed successful.  
3.3 Synthesis of the PEG linker O-benzyl tetra ethylene glycol. 
In the original plan for this project, a tosylated tetra ethylene glycol chain was synthesized. This was done 
by adding p-toluene sulfonyl chloride, tetra ethylene glycol and 16M KOH in THF. After the solution was 
refluxed for 1 hour, the reaction stirred at room temperature overnight. The product was extracted using 
diethyl ether and washed with a brine solution. The resulting product was dried using magnesium sulfate 
and condensed using rotary evaporation. The reaction yielded both a monosubstituted tosyl-PEG as well 
as a disubstituted tosyl-PEG. This created a problem when it came time to separate the products. Where 
both had extremely similar polarities, a TLC plate with various combinations of solvent systems did not 
allow it to move from the baseline. Therein the plan was diverged.  
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The next idea was to add a benzyl group to the tetra ethylene glycol. This was done as shown in 
experimental 2.2.1 9. Once the monosubstituted benzyl-PEG was isolated, a tosyl group was added using 
p-toluene sulfonyl chloride, DMAP, and triethyl amine in DCM. This reaction was done under argon and 
allowed to stir overnight at room temperature. The resulting product was checked against starting 
materials by using a 1:1(v/v) hexanes: ethyl acetate solvent system. To purify, a separatory funnel was 
used by extracting with ethyl acetate and washing with a 5% sodium bicarbonate wash, twice, and a brine 
wash, twice. The resulting solution was concentrated using rotary evaporation. 
3.4 Coupling of the PEG linker  
After the succession of the targeted phenanthroline ligand and the PEG linker, the next step was to couple 
this ligand to the PEG linker. Another member of the research group had tried to couple the amine 
phenanthroline to the tosylated monosubstituted benzyl-PEG linker. This reaction was deemed 
unsuccessful; therefore, there was another deviation in the project’s plan. Stated in the previous section 
3.2, the aminephen 2 was unsuccessful in the coupling reaction, so a better leaving group was needed to 
be able to perform the needed SN2 reaction to be able to couple the two compounds.  
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3.5 Synthesis of Eu(tta)3 complexes 
Three different 5-substituted ligands were synthesized in this project containing a nitro (2), amine (3) and 
a Bromo acetamide (4) group.  Each of these groups are expected to influence the luminescent properties 
of their europium complexes differently.  The nitro group is a powerful electron with-drawing group, the 
amine is a powerful electron donating group and the acetamide is a moderate electron donating-group.  
Europium-TTA complexes of all three ligands and phenanthroline (R = H) were synthesized and their 
quantum yields measured to determine their ability as fluorescent dyes.  
 
 
 
 
 
 
 
 
 
Figure 10: Synthetic strategy for chelation of the phenanthroline ligands to Eu(tta)3.  
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most of the hydroxide from the NaOH solution has turned into water and allows the sodium and chloride 
to form a salt whilst the europium forms six bonds with three of the deprotonated TTA as shown in figure 
10. The washing of the resulting product allows for the remaining salt to be removed from the precipitate. 
The success of this reaction was determined by shining the complex under a UV lamp to display its 
luminescent properties.  
 The chelation of this complex to the organic ligands involves separately preparing solutions of 
Eu(tta)3 and the phenanthroline ligand in dichloromethane. By keeping them separated and adding them 
dropwise this allows for there to be control over the selectivity of the chelation between the Eu(tta)3 and 
the nitrogen locations of the phenanthroline ligands. The resulting complexes were characterized by UV-
Vis and Fluorescence spectroscopy. 
3.6 UV-Vis and Fluorescence Spectra of Eu(tta)3(n-phenanthroline) complexes 
Qualitative spectra were taken for each ligand, complex, and reference sample. In figure 11, 
phenanthroline was shown to absorb around 265 nm. This proves that the absorbance around 340 in figure 
12 is TTA, which matches known absorbance values for TTA. This trend follows with the phenanthroline 
ligands with different functional groups show in figures 11 and 12. Upon chelation of the phenanthroline 
ligands, the absorption spectra are shown to have two peaks, one peak between 240 and 300 and one peak 
between 330 and 360. These peaks are the phenanthroline ligands and the TTA respectively. The TTA 
peak is displayed to have shifted once the organic ligands were chelated to the europium. The 
fluorescence spectra display appropriate peaks for the fluorescence of TTA in figure 13.  
 Although there are noticeable differences of the UV-Vis spectra for each organic ligand and 
complex, the fluorescence spectra for all four complexes look almost identical in that their emission 
wavelength is the same (615nm).  This is expected since the fluorescence of europium results from 
electronic transitions in f-orbitals whose energies are not involved in binding to ligands.  However, the 
different ligands do affect the intensities of emission and are all different.  The two complexes with the 
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lower quantum yields, nitrophenanthroline (2)  and BPAH (3), also have lower intensities. This is 
extremely important when looking at the absorbance spectra for BPAH in figure 11. In order to get a 
spectrum with a smooth curve and noticeable peaks, the concentration had to be significantly higher for 
this ligand than the others. This is also true for the Eu(tta)3-BPAH complex in figure 12, as well. 
However, the fluorescence spectra for the larger concentration has a lower intensity of the main 615 nm 
peak. This is directly correspondent to the low quantum yield of the complex being less than 1%, (table 
1.)  
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Figure 11: UV-Vis spectra of phenanthroline ligands 
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Figure 12: UV-Vis spectra of Eu(tta)3-phenanthroline complexes 
0
0.5
1
1.5
2
235 255 275 295 315 335 355 375 395 415
A
b
so
b
an
ce
 
wavelength (nm)
Eu(tta)3-BHAP 
0
0.1
0.2
0.3
0.4
0.5
245 265 285 305 325 345 365 385
A
b
so
rb
an
ce
Wavelength (nm)
Eu(tta)3-1,10-phenanthroline
0
0.1
0.2
0.3
0.4
0.5
250 270 290 310 330 350 370 390
A
b
so
rb
an
ce
Wavelength (nm)
Eu(tta)3-5-nitro-1,10-phenanthroline
0
0.1
0.2
0.3
0.4
0.5
250 270 290 310 330 350 370 390
A
b
so
rb
an
ce
Wavelength (nm)
Eu(tta)3-5-amine-1,10-
phenanthroline
29 
 
  
  
Figure 13: Fluorescence spectra of Eu(tta)3-phenanthroline complexes excited at 340 nm 
3.7 Quantum Yield  
Quantum yield is a ratio of the number of photons absorb in comparison to the number of photons that are 
emitted by a fluorophore.  Quantum yield is determined by measuring the UV-Vis absorbance and 
fluorescence spectra of each sample thrice, over a period of three day. The data that is collected is then 
input into Equation 1 displayed in Chapter 2 section 2.1.5. The quantum yields of each complex are 
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shown in table 1. The quantum yield is used to measure the fluorescence efficiency of the europium 
complexes synthesized in this study.  Quantum yield is simply the ratio of the number photons emitted to 
the number of photons absorbed.     
 Equation 1     
𝜙𝑆 = 𝜙𝑅
𝐴𝑏𝑠𝑅
𝐴𝑏𝑠𝑆
𝐴𝑆
𝐴𝑅
𝑛𝑆
2
𝑛𝑅
2  
 
Where Abs is the absorbance, A is the area under the luminescence curve, and n is the refractive index of 
the solvent. The subscripts R and S are representative of reference sample and sample respectively.   Phi 
(φ) is representative of quantum yield itself. The reference sample that was used was Cresyl violet, with a 
known quantum yield of 0.54, or 54%. 
Within this table, and discussed in prior sections, the quantum yield of the Eu(tta)3BPAH 
complex is significantly lower than that of the other chelated ligand complexes. This is unfortunate; 
however, we still feel that these systems can work as biological imaging reagents.  Ideally the complex 
would have a high quantum yield which would allow lower concentration of the dye to be used in 
imaging.  With some investigation as to why this has happened, the absorption and fluorescence spectra 
of his complex has been taken into accord. The absorption spectra had to be at a greater concentration to 
obtain a readable spectrum, as well as the fluorescence of the complex is at a lesser intensity as well. With 
the objective of the fluorophore to be able to luminesce at greater intensities than that of others, this had 
presented a problem. The reason in using BPAH was to have a better SN2 reaction to attach to the PEG 
linker, however if the quantum yield is low then the problem arises as to why and how to fix this problem, 
or to try another method for coupling to the PEG linker. The first idea was to see if the BPAH had a 
significant fluorescence itself, as opposed to other organic ligands. This proved to be ineffective as it has 
no considerable difference to other organic ligands. Next, the structure itself was taken into account. The 
Eu(tta)3aminephen has the highest quantum yield out of all complexes because it is such a good electron 
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donator to the system. When looking at the structure of BPAH [3], one would assume that the attachment 
of the bromo acetamide wouldn’t have made a significant difference, however the carbonyl oxygen acts 
as an electron magnet. This restricts the electrons on the amine from conjugating with the phenanthroline 
to aid in the antenna effect. This concludes that there needs to be future work to be able to reduce the 
carbonyl oxygen or to remove it altogether.  
Table 1: Quantum Yield Values 
Complex Quantum yield (%) Std Dev 
Eu(tta)3phen 4.83 0.815 
Eu(tta)3nitrophen 2.78 0.523 
Eu(tta)3aminephen 5.02 1.14 
Eu(tta)3BPAH 0.417 0.107 
 
3.8 Future work 
Future work for this project would entail designing a better ligand to attach to the linker without hindering 
the quantum yield of the lanthanide (III) complex. This could also necessitate having a better functional 
group on the PEG linker to be able to utilize the aminephenanthroline. This would ensure that the 
quantum yield would not be hindered by any groups on the ligand. Future work would also include 
attaching the MSH-4 peptide to the PEG linker with the ligand already coupled. Having the linker, ligand, 
and peptide attached would presumably be unchallenging to chelate the lanthanide (III) complex.    
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CHAPTER 4: SUPPLEMENTAL DATA 
This chapter includes all spectra referenced in previous chapters. The solvents used are listed within the 
experimental chapter for each compound respectively. The spectra included in this chapter are of 
compounds that were synthesized within the lab, with the exception of one UV spectra for commercially 
purchased 1,10-phenanthroline.  
4.1 NMR and IR spectra  
4.1.1 5-nitro-1,10-phenanthroline, (nitrophenanthroline) [1]
 
13C NMR nitrophenanthroline 
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N
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4.1.2 5-amine-1,10-phenanthroline,(aminephenanthroline) [2] 
 
  13C NMR-animephenanthroline 
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  1H NMR- aminephenanthroline (zoomed in) 
 
 IR-aminephenanthroline 
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4.1.3 2-bromo-N-(1,10-phenanthroline-5-yl) acetamide hydrobromide, (BPAH) [3]  
 
 13C NMR- BPAH 
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4.1.4 Monobenzyl protected polyethylene glycol linker [9]19,13 
 
 
 
 
 
 
 
 
 
1H NMR Monobenzyl protected polyethylene glycol linker 
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CDCl3 
13C NMR Monobenzyl protected polyethylene glycol linker 
IR Monobenzyl protected polyethylene glycol linker 
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4.2 LCMS and MS spectra22 
 
LC-MS chromotogram of MSH-4 peptide 
 
Mass spectra of MSH-4 peptide 
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4.3 UV-Vis and Fluorescence spectra 
  
  
UV-Vis spectra of phenanthroline ligands 
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UV-Vis spectra of Eu(tta)3-phenanthroline complexes 
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Fluorescence spectra of Eu(tta)3-phenanthroline complexes excited at 340 nm 
4.3.1 Quantum Yield Table 
Table 2: Quantum Yield Values 
Complex Quantum yield (%) Std Dev 
Eu(tta)3phen 4.83 0.815 
Eu(tta)3nitrophen 2.78 0.523 
Eu(tta)3aminephen 5.02 1.14 
Eu(tta)3BPAH 0.417 0.107 
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